Tags

Type your tag names separated by a space and hit enter

Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model.
Allergy. 2008 Sep; 63(9):1164-76.A

Abstract

BACKGROUND

The migration and in situ differentiation of CD34(+) progenitors contribute to inflammatory eosinophilia in asthma and corticosteroids have been widely used in asthma. However, little is know about whether and how corticosteroids modulate the migration and differentiation of CD34(+) progenitors. This study was aimed to investigate the impact of anti-CC chemokine receptor 3 (CCR3) or dexamethasone on inflammatory eosinophilia in asthma and possible mechanism(s) underlying the action of dexamethasone or anti-CCR3 on migration and differentiation of CD34(+) progenitors in asthmatic context.

METHODS

Using an asthmatic mouse model, airway inflammation of anti-CCR3- or dexamethasone-treated mice and that of controls were characterized. And the migration and differentiation of CD34(+) progenitor cells were analyzed in vivo, ex vivo or in vitro.

RESULTS

Treatment with anti-CCR3 or dexamethasone significantly inhibited allergen-induced eosinophilia and CD34(+) progenitor cell infiltration in the lung, which was accompanied by lower levels of airway hyper-responsiveness and mucus production. Moreover, anti-CCR3 inhibited the eotaxin-mediated migration and IL-5/eotaxin-induced differentiation of CD34(+) progenitors in vitro. Dexamethasone was also shown to mitigate eotaxin-mediated migration and IL-5 or eotaxin-promoted differentiation of CD34(+) progenitor cells ex vivo, which were associated with the down-regulation of CCR3 expression on bone marrow progenitor cells.

CONCLUSIONS

Treatment with anti-CCR3 or dexamethasone can inhibit the migration and differentiation of CD34(+) progenitor cells by regulating the eotaxin/CCR3 axis in asthmatic mice. Our findings provide new insights into understanding the mechanism(s) underlying the action of dexamethasone and CCR3-mediated signaling in allergic inflammation and aid in the design of new immunotherapy for intervention of human asthma.

Authors+Show Affiliations

Department of Respiratory Disease, Second Affiliated Hospital, Zhejiang University College of Medicine, The Institute of Respiratory Diseases of Zhejiang University, Hangzhou, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18699933

Citation

Ben, S, et al. "Treatment With anti-CC Chemokine Receptor 3 Monoclonal Antibody or Dexamethasone Inhibits the Migration and Differentiation of Bone Marrow CD34 Progenitor Cells in an Allergic Mouse Model." Allergy, vol. 63, no. 9, 2008, pp. 1164-76.
Ben S, Li X, Xu F, et al. Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy. 2008;63(9):1164-76.
Ben, S., Li, X., Xu, F., Xu, W., Li, W., Wu, Z., Huang, H., Shi, H., & Shen, H. (2008). Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy, 63(9), 1164-76. https://doi.org/10.1111/j.1398-9995.2008.01747.x
Ben S, et al. Treatment With anti-CC Chemokine Receptor 3 Monoclonal Antibody or Dexamethasone Inhibits the Migration and Differentiation of Bone Marrow CD34 Progenitor Cells in an Allergic Mouse Model. Allergy. 2008;63(9):1164-76. PubMed PMID: 18699933.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. AU - Ben,S, AU - Li,X, AU - Xu,F, AU - Xu,W, AU - Li,W, AU - Wu,Z, AU - Huang,H, AU - Shi,H, AU - Shen,H, PY - 2008/8/14/pubmed PY - 2009/1/17/medline PY - 2008/8/14/entrez SP - 1164 EP - 76 JF - Allergy JO - Allergy VL - 63 IS - 9 N2 - BACKGROUND: The migration and in situ differentiation of CD34(+) progenitors contribute to inflammatory eosinophilia in asthma and corticosteroids have been widely used in asthma. However, little is know about whether and how corticosteroids modulate the migration and differentiation of CD34(+) progenitors. This study was aimed to investigate the impact of anti-CC chemokine receptor 3 (CCR3) or dexamethasone on inflammatory eosinophilia in asthma and possible mechanism(s) underlying the action of dexamethasone or anti-CCR3 on migration and differentiation of CD34(+) progenitors in asthmatic context. METHODS: Using an asthmatic mouse model, airway inflammation of anti-CCR3- or dexamethasone-treated mice and that of controls were characterized. And the migration and differentiation of CD34(+) progenitor cells were analyzed in vivo, ex vivo or in vitro. RESULTS: Treatment with anti-CCR3 or dexamethasone significantly inhibited allergen-induced eosinophilia and CD34(+) progenitor cell infiltration in the lung, which was accompanied by lower levels of airway hyper-responsiveness and mucus production. Moreover, anti-CCR3 inhibited the eotaxin-mediated migration and IL-5/eotaxin-induced differentiation of CD34(+) progenitors in vitro. Dexamethasone was also shown to mitigate eotaxin-mediated migration and IL-5 or eotaxin-promoted differentiation of CD34(+) progenitor cells ex vivo, which were associated with the down-regulation of CCR3 expression on bone marrow progenitor cells. CONCLUSIONS: Treatment with anti-CCR3 or dexamethasone can inhibit the migration and differentiation of CD34(+) progenitor cells by regulating the eotaxin/CCR3 axis in asthmatic mice. Our findings provide new insights into understanding the mechanism(s) underlying the action of dexamethasone and CCR3-mediated signaling in allergic inflammation and aid in the design of new immunotherapy for intervention of human asthma. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/18699933/Treatment_with_anti_CC_chemokine_receptor_3_monoclonal_antibody_or_dexamethasone_inhibits_the_migration_and_differentiation_of_bone_marrow_CD34_progenitor_cells_in_an_allergic_mouse_model_ L2 - https://doi.org/10.1111/j.1398-9995.2008.01747.x DB - PRIME DP - Unbound Medicine ER -